|
Device | INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE |
Generic Name | Filler, recombinant human bone morphogenetic protein, collagen scaffold with metal prosthesis, osteoinduction |
Applicant | Medtronic Sofamor Danek USA, Inc. 1800 Pyramid Place Memphis, TN 38132 |
PMA Number | P000058 |
Date Received | 12/22/2000 |
Decision Date | 07/02/2002 |
Product Code |
NEK |
Docket Number | 02M-0310 |
Notice Date | 07/11/2002 |
Advisory Committee |
Orthopedic |
Expedited Review Granted? | Yes |
Combination Product | Yes |
Recalls | CDRH Recalls |
Approval Order Statement APPROVAL FOR THE INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE. THIS DEVICE IS INDICATED FOR SPINAL FUSION PROCEDURES IN SKELETALLY MATURE PATIENTS WITH DEGENERATIVE DISC DISEASE (DDD) AT ONE LEVEL FROM L4-S1. DDD IS DEFINED AS DISCOGENIC BACK PAIN WITH DEGENERATION OF THE DISC CONFIRMED BY PATIENT HISTORY, FUNCTION DEFICIT AND/OR NEUROLOGICAL DEFICIT AND RADIOGRAPHIC STUDIES. THESE DDD PATIENTS MAY ALSO HAVE UP TO GRADE I SPONDYLOLISTHESIS AT THE INVOLVED LEVEL. INFUSE BONE GRAFT/LT-CAGE DEVICES ARE TO BE IMPLANTED VIA AN ANTERIOR OPEN OR AN ANTERIOR LAPAROSCOPIC APPROACH. PATIENTS RECEIVING THE INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE SHOULD HAVE HAD AT LEAST SIX MONTHS OF NONOPERATIVE TREATMENT PRIOR TO TREATMENT WITH THE INFUSE BONE GRAFT/LT-CAGE DEVICE. |
Approval Order | Approval Order |
Summary | Summary of Safety and Effectiveness |
Labeling | Labeling
|
Supplements: |
S001 S002 S003 S004 S005 S006 S007 S008 S009 S010 S014 S015 S016 S017 S019 S020 S021 S022 S023 S025 S026 S027 S028 S029 S030 S031 S032 S033 S034 S036 S037 S038 S039 S040 S041 S042 S043 S044 S045 S046 S047 S048 S049 S050 S051 S052 S053 S054 S056 S057 S058 S059 S060 S061 S062 S063 S064 S065 S067 S068 S069 S070 S071 S072 S073 S074 S075 S076 S077 S078 S079 S080 S081 S082 S083 S084 S085 S086 S087 S088 S089 S090 S091 S093 |